Evidence map›Paper›PMID 26908119›Full record

ReviewDer Urologe. Ausg. A2016

[Influence of drugs on urological diseases].

P A Thürmann

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

P A ThürmannPhilipp-Klee-Institut für Klinische Pharmakologie, HELIOS Klinikum Wuppertal, Wuppertal, Deutschland. petra.thuermann@helios-kliniken.de.
Helios Universitätsklinikum Wuppertal · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A number of drugs prescribed for the treatment of various diseases can induce urological symptoms as side effects. Antihypertensive drugs (particularly alpha blockers) can result in stress incontinence, whereas selective serotonin reuptake inhibitors (SSRI) can cause urge incontinence and estrogen promotes both forms. A wide range of drugs with anticholinergic activity, among them neuroleptics, tricyclic antidepressants and certain drugs used in airway disorders are associated with urinary retention. Only very few drugs bear a relevant risk for urolithiasis, i. e. the diuretic triamterene and protease inhibitors, such as indinavir; however, the widely used combination of calcium and vitamin D supplementation for prevention of osteoporosis may be an underdiagnosed cause of renal calculi. Drug-induced sexual dysfunction is a frequent side effect of antihypertensive treatment, particularly with beta adrenoceptor blockers and diuretics. The SSRI and some neuroleptics can also impair sexual function.

Indexed as

Adrenergic beta-AntagonistsAntihypertensive AgentsCholinergic AntagonistsDiureticsDose-Response Relationship, DrugEvidence-Based MedicineHumansSerotonin and Noradrenaline Reuptake InhibitorsTreatment OutcomeUrologic DiseasesVitamin DAdrenergic beta-AntagonistsAntihypertensive AgentsCholinergic AntagonistsDiureticsSerotonin and Noradrenaline Reuptake InhibitorsVitamin DAntihypertensive agentsDrug-induced urinary incontinenceSexual dysfunctionUrinary retentionUrolithiasis

Identifiers

PMID26908119
OpenAlexW2287153569

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.